Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 61, Issue 10, 2014, Pages 1816-1821

  Kolb, E Anders ^a   Gorlick, Richard ^b   Billups, Catherine A ^c   Hawthorne, Thomas ^d   Kurmasheva, Raushan T ^e   Houghton, Peter J ^e   Smith, Malcolm A ^f  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d Celldex Therapeutics Inc   (United Kingdom)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody drug conjugate; Developmental therapeutics; Osteosarcoma; Preclinical testing

Indexed keywords

GLEMBATUMUMAB VEDOTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANTIBODY-DRUG CONJUGATE; DEVELOPMENTAL THERAPEUTICS; OSTEOSARCOMA; PRECLINICAL TESTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; OSTEOSARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908501278     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25099     Document Type: Article

References (29)

1. Ripoll VM, Irvine KM, Ravasi T, et al. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 2007; 178:6557-6566.
2. Tomihari M, Hwang SH, Chung JS, et al. Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol 2009; 18:586-595.
3. Bachner D, Schroder D, Gross G. mRNA expression of the murine glycoprotein (transmembrane) nmb (Gpnmb) gene is linked to the developing retinal pigment epithelium and iris. Brain Res Gene Expr Patterns 2002; 1:159-165.
4. Chung JS, Sato K, Dougherty II, et al. DC-HIL is a negative regulator of T lymphocyte activation. Blood 2007; 109:4320-4327.
5. Chung JS, Dougherty I, Cruz PD Jr, et al. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol 2007; 179:5778-5784.
6. Schwarzbich MA, Gutknecht M, Salih J, et al. The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. Cancer Immunol Immunother 2012; 61:193-202.
7. Onaga M, Ido A, Hasuike S, et al. Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 2003; 39:779-785.
8. Rose AA, Siegel PM. Osteoactivin/HGFIN: Is it a tumor suppressor or mediator of metastasis in breast cancer? Breast Cancer Res 2007; 9:403.
9. Rose AA, Grosset AA, Dong Z, et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010; 16:2147-2156.
10. Kuan CT, Wakiya K, Dowell JM, et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006; 12:1970-1982.
11. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12:1373-1382.
12. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14:154-169.
13. Pollack VA, Alvarez E, Tse KF, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 2007; 60:423-435.
14. Hamid O, Sznol M, Pavlick AC, et al. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. J Clin Oncol 2010; 28: (May 20 Supplement) Abstract 8525.
15. Saleh MN, Bendell JC, Rose A, et al. Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE). J Clin Oncol 2010; 28: (May 20 Supplement), Abstract 1095.
16. Yardley DA, Weaver R, Melisko ME, et al. A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study. Cancer Res 2012; 72: Abstract nr P26-10-01.
17. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49:928-940.
18. Kolb EA, Gorlick R, Reynolds CP, et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013 60:1325-1332.
19. Sutow WW. Vincristine (NSC-67574) therapy for malignant solid tumors in children (except Wilms' tumor). Cancer Chemother Rep 1968; 52:485-487.
20. Sutow WW, Vietti TJ, Fernbach DJ, et al. Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma. Cancer Chemother Rep 1971; 55:67-78.
21. Rosen G, Nirenberg A, Caparros B, et al. Osteogenic sarcoma: Eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). Natl Cancer Inst Monogr 1981; 213-220.
22. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet 1997; 350:911-917.
23. Edmonson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 1984; 2:152-156.
24. Krailo M, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: A report from the Childrens Cancer Study Group. Med Pediatr Oncol 1987; 15:69-77.
25. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol 1987; 5:21-26.
26. Pratt CB, Champion JE, Fleming ID, et al. Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. Cancer 1990; 65:439-445.
27. Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: Evidence of activity in rhabdomyosarcoma. Cancer 2002; 94:3263-3268.
28. Morton CL, Favours EG, Mercer KS, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 2007; 25:285-295.
29. Qian X, Mills E, Torgov M, et al. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol 2008; 2:81-93.